VTYX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Ventyx Biosciences Inc

NASDAQ | VTYX

6.89

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$275.25M

Market Cap

-

P/E Ratio

-1.66

EPS

$4.11

52 Week High

$0.78

52 Week Low

HEALTHCARE

Sector

VTYX Chart

Recent Chart
Price Action

VTYX Technicals

Tags:

VTYX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

Revenue & Profitability

Earnings Performance

VTYX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $277M
Total Current Assets $230M
Cash And Cash Equivalents At Carrying Value $27M
Cash And Short Term Investments $27M
Inventory -
Current Net Receivables $1M
Total Non Current Assets $47M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $36M
Short Term Investments $190M
Other Current Assets $11M
Other Non Current Assets -
Total Liabilities $23M
Total Current Liabilities $13M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt $2.1M
Total Non Current Liabilities $9.7M
Capital Lease Obligations $11M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $11M
Other Current Liabilities $7.5M
Other Non Current Liabilities -
Total Shareholder Equity $254M
Treasury Stock -
Retained Earnings -$554M
Common Stock $7K
Common Stock Shares Outstanding $68M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$131M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.3M
Capital Expenditures $241K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$16M
Cashflow From Financing $122M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$135M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$1.3M
Total Revenue $0
Cost Of Revenue $1.3M
Costof Goods And Services Sold $1.3M
Operating Income -$148M
Selling General And Administrative $31M
Research And Development $117M
Operating Expenses $148M
Investment Income Net -
Net Interest Income $13M
Interest Income $13M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.3M
Income Before Tax -$135M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$135M
Comprehensive Income Net Of Tax -
Ebit -$135M
Ebitda -$134M
Net Income -$135M

VTYX News

VTYX Profile

Ventyx Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, dedicated to developing novel small molecule therapeutics for inflammatory and autoimmune disorders. The company is advancing a promising pipeline of drug candidates that target critical pathways involved in these diseases, aiming to meet substantial unmet medical needs. With a robust emphasis on research and development, Ventyx is well-positioned to provide innovative treatment solutions that can improve patient outcomes and capitalize on emerging opportunities within the dynamic biopharmaceutical market.

YYAI
-51.03%
$0.09
BYND
-17.31%
$2.96
YDKG
+6.61%
$0.07
SCNX
+204.44%
$1.73
VHAI
0.00%
$0.00
F
-0.68%
$12.34
CGBS
-39.47%
$0.03
AIRE
+42.68%
$1.01
RGTI
-9.85%
$36.06
TSLA
+1.78%
$446.80
VTYX
+78.62%
$6.89
BURU
-7.35%
$0.33
QBTS
+12.84%
$30.79
RIG
+11.98%
$3.83
NVDA
+1.40%
$182.82
NOK
+10.87%
$6.15
ADAP
-4.27%
$0.06
AAL
+5.50%
$12.75
IONZ
-15.47%
$3.93
MSAI
+52.43%
$1.02
T
-3.85%
$24.56
WTO
-7.45%
$0.06
AXDX
-61.36%
$0.03
AREB
+42.79%
$3.07
BITF
+4.28%
$4.10
IONQ
+8.09%
$59.94
INTC
+2.50%
$37.84
DNN
+1.83%
$2.77
PLUG
+0.68%
$2.94
RGTZ
-22.52%
$14.48
RBNE
+25.98%
$1.60
SMCI
-8.21%
$48.18
TLRY
+3.44%
$1.50
QUBT
+6.31%
$15.80
SOFI
+4.54%
$28.42
ABEV
+0.68%
$2.21
GRAB
+1.60%
$5.71
MARA
-4.58%
$19.14
VIVK
+9.26%
$0.26
RMBL
+60.50%
$3.21
ETHD
-2.68%
$3.99
ADD
-25.47%
$0.05
SGBX
+26.75%
$2.89
CAN
+7.89%
$1.83
BBD
+1.81%
$3.36
GOOGL
+0.49%
$251.69
SRM
+53.27%
$10.30
RF
+0.26%
$24.17
ACHR
+0.53%
$10.91
QS
+9.83%
$14.91
LAES
+7.61%
$5.81
VZ
-2.87%
$38.65
GPUS
-1.16%
$0.38
JOBY
+1.90%
$15.76
AMD
+1.82%
$234.44
RXRX
-0.26%
$5.73
TNGX
-7.85%
$7.98
CUTR
-10.19%
$0.09
BTG
+0.89%
$5.25
WLGS
-5.57%
$0.04
UUUU
-7.71%
$20.98
PLTR
+3.09%
$180.91
BTBT
+4.87%
$3.76
IBIO
-11.87%
$1.22
DVLT
+6.30%
$2.27
VLY
+4.24%
$10.55
ONDS
+6.15%
$7.15
ETWO
0.00%
$3.30
AMC
0.00%
$2.75
CIFR
+8.31%
$17.45
WBD
+3.77%
$21.30
PFE
-0.34%
$24.63
SOUN
+4.02%
$18.47
TE
-9.99%
$3.69
NIO
+1.24%
$6.92
AFMD
-34.94%
$0.18
BTE
+5.72%
$2.40
NVTS
+1.47%
$13.80
IREN
+9.90%
$56.96
NEHC
-12.47%
$3.79
LUV
-5.66%
$31.84
RR
+7.71%
$5.45
EONR
-13.70%
$0.54
OPI
-16.97%
$0.20
ELBM
-3.01%
$1.60
KMI
-3.01%
$26.73
AAPL
+0.51%
$259.79
HPE
+0.48%
$23.20
DNUT
-0.91%
$3.99
KLG
-9.05%
$13.35
AMZN
+1.38%
$220.96
SCWO
+43.76%
$0.53
HOOD
+6.12%
$135.00
PBR
+1.79%
$11.94
APLD
+10.18%
$33.73
GRYP
-10.38%
$1.38
RIVN
+0.92%
$13.04
MODV
-25.22%
$0.43
SNAP
+1.67%
$7.90
VALE
-0.26%
$11.49
YYAI
-51.03%
$0.09
BYND
-17.31%
$2.96
YDKG
+6.61%
$0.07
SCNX
+204.44%
$1.73
VHAI
0.00%
$0.00
F
-0.68%
$12.34
CGBS
-39.47%
$0.03
AIRE
+42.68%
$1.01
RGTI
-9.85%
$36.06
TSLA
+1.78%
$446.80
VTYX
+78.62%
$6.89
BURU
-7.35%
$0.33
QBTS
+12.84%
$30.79
RIG
+11.98%
$3.83
NVDA
+1.40%
$182.82
NOK
+10.87%
$6.15
ADAP
-4.27%
$0.06
AAL
+5.50%
$12.75
IONZ
-15.47%
$3.93
MSAI
+52.43%
$1.02
T
-3.85%
$24.56
WTO
-7.45%
$0.06
AXDX
-61.36%
$0.03
AREB
+42.79%
$3.07
BITF
+4.28%
$4.10
IONQ
+8.09%
$59.94
INTC
+2.50%
$37.84
DNN
+1.83%
$2.77
PLUG
+0.68%
$2.94
RGTZ
-22.52%
$14.48
RBNE
+25.98%
$1.60
SMCI
-8.21%
$48.18
TLRY
+3.44%
$1.50
QUBT
+6.31%
$15.80
SOFI
+4.54%
$28.42
ABEV
+0.68%
$2.21
GRAB
+1.60%
$5.71
MARA
-4.58%
$19.14
VIVK
+9.26%
$0.26
RMBL
+60.50%
$3.21
ETHD
-2.68%
$3.99
ADD
-25.47%
$0.05
SGBX
+26.75%
$2.89
CAN
+7.89%
$1.83
BBD
+1.81%
$3.36
GOOGL
+0.49%
$251.69
SRM
+53.27%
$10.30
RF
+0.26%
$24.17
ACHR
+0.53%
$10.91
QS
+9.83%
$14.91
LAES
+7.61%
$5.81
VZ
-2.87%
$38.65
GPUS
-1.16%
$0.38
JOBY
+1.90%
$15.76
AMD
+1.82%
$234.44
RXRX
-0.26%
$5.73
TNGX
-7.85%
$7.98
CUTR
-10.19%
$0.09
BTG
+0.89%
$5.25
WLGS
-5.57%
$0.04
UUUU
-7.71%
$20.98
PLTR
+3.09%
$180.91
BTBT
+4.87%
$3.76
IBIO
-11.87%
$1.22
DVLT
+6.30%
$2.27
VLY
+4.24%
$10.55
ONDS
+6.15%
$7.15
ETWO
0.00%
$3.30
AMC
0.00%
$2.75
CIFR
+8.31%
$17.45
WBD
+3.77%
$21.30
PFE
-0.34%
$24.63
SOUN
+4.02%
$18.47
TE
-9.99%
$3.69
NIO
+1.24%
$6.92
AFMD
-34.94%
$0.18
BTE
+5.72%
$2.40
NVTS
+1.47%
$13.80
IREN
+9.90%
$56.96
NEHC
-12.47%
$3.79
LUV
-5.66%
$31.84
RR
+7.71%
$5.45
EONR
-13.70%
$0.54
OPI
-16.97%
$0.20
ELBM
-3.01%
$1.60
KMI
-3.01%
$26.73
AAPL
+0.51%
$259.79
HPE
+0.48%
$23.20
DNUT
-0.91%
$3.99
KLG
-9.05%
$13.35
AMZN
+1.38%
$220.96
SCWO
+43.76%
$0.53
HOOD
+6.12%
$135.00
PBR
+1.79%
$11.94
APLD
+10.18%
$33.73
GRYP
-10.38%
$1.38
RIVN
+0.92%
$13.04
MODV
-25.22%
$0.43
SNAP
+1.67%
$7.90
VALE
-0.26%
$11.49
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.